AI-Powered Pet Longevity Platform Raising $1.6M

A category-defining longevity platform for companion animals, integrating AI diagnostics, digital twins, precision supplements, and breakthrough drug development. The mission: to keep dogs healthier for longer by spotting health issues early and delivering personalized, evolving care plans. Problem- Dogs age exponentially, with >80% of diseases caught only once symptomatic.- Current treatments are reactive, one-size-fits-all, and often too late.- Owners demand better solutions: 93–95% consider pets family; 86% say they’d pay “whatever it takes” for pet health. Solution At-home diagnostics & continuous tracking feeding into an AI-powered digital twin. Personalized interventions covering nutrition, disease prevention, recovery, and longevity strategies. Proprietary supplements and an exclusive global license on a patented longevity drug showing >95% symptom reversal in preclinical data. Business Model- Subscription plans ($24–99/month) for diagnostics, AI health insights, and personalized interventions.- Supplements & boosters (direct-to-consumer, GMP-cleared US/UK/EU).- Drug development (exclusive licensing + equity stake in a longevity lab).- Data monetization via multi-omic, longitudinal health datasets. Market Opportunity- Global petcare market: ~$600B by###-###-#### % CAGR).- AI in animal health: ~$6B by###-###-#### % CAGR).- Target market: $37B TAM / $13B SAM / $300M SOM.- Long-term upside from proprietary longevity drug portfolio. Traction- Digital twin and AI engine operational.- Exclusive diagnostic lab partnership, securing high-value data ownership.- Proprietary supplements launched with GMP partner clearance.- Global license on longevity drug + 25% equity in R&D lab and patent portfolio.- 10+ GTM and university partnerships in place. Investment Opportunity The company is raising $1.6M growth capital via a SAFE (valuation cap: $12M, 15% discount) to: - Fund market launch and commercial rollout.- Complete drug trials and validate additional IP.- Extend runway ~18 months (assuming zero revenue).- Prepare for Series A in 2026 targeting >$50M valuation. Why Now- Science-backed innovation meets surging consumer demand for pet wellness and lifespan extension.- Pet subscription models are scaling at 13.5% CAGR.- First-mover advantage in combining diagnostics, AI digital twins, and drug development. Team Led by a seasoned founding team with biotech IPO and multiple exit experience, combined with AI leaders from Google DeepMind and commercial operators who have closed $500M+ partnership deals. Supported by an advisory board spanning veterinary science, healthcare, and capital markets. A high-growth venture at the intersection of AI, biotech, and pet wellness — with multiple scalable revenue streams and non-linear upside from proprietary longevity drugs